Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk Stock Jumps
Why Novo Nordisk Stock Is Soaring Today
Shares of Novo Nordisk (NYSE: NVO) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but gained as much as 5.8% earlier in the day. The leg up comes as the S&P 500 (SNPINDEX: ^GSPC) gained 0.
Novo Nordisk Stock Slides Before Q4 Earnings: Analysts Still See 68% Upside
Novo Nordisk (NVO) reports Q4 earnings with expectations of 86 cents EPS and $11.40B revenues. Stock down 29.55% YOY, 4.81% YTD. Analysts see 68% upside.
Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns.
Novo Nordisk stock rose Wednesday after the drugmaker reported quarterly earnings above analysts’ expectations, but forecast slower growth ahead.Novo posted fourth-quarter earnings of 6.34 ($0.88) Danish kroner a share on sales of 85.
5h
Novo Nordisk’s (NVO) CEO Is Not Worried About Government Price Negotiations
Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...
16h
Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...
14h
Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...
1h
Shareholders that Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky about Pending Class Action - NVO
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Novo Nordisk
New York
Class action
Wegovy
Ozempic
Feedback